CLDI — Calidi Biotherapeutics, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2020-04-13.
Performance
Technicals
Others in Healthcare
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2025-12-12 | Camaisa Allan Director | Open-market sale | 850 | 1.46 | 1.2K |
| 2025-08-21 | Leftwich Scott Director | Open-market purchase | 125.0K | 2.00 | 250.0K |
| 2025-08-21 | Schoeneck James A Director | Open-market purchase | 75.0K | 2.00 | 150.0K |
| 2025-08-21 | Poma Eric E Chief Executive Officer | Open-market purchase | 25.0K | 2.00 | 50.0K |
| 2025-08-21 | Jackson Andrew C. Chief Financial Officer | Open-market purchase | 2.5K | 2.00 | 5.0K |
| 2024-12-31 | Stewart Alan R. Director | Grant or award | 12.8K | — | — |
| 2024-12-31 | Leftwich Scott Director | Grant or award | 11.7K | — | — |
| 2024-12-17 | Camaisa Allan CEO and Chairman of the Board | Open-market sale | 10.0K | 1.62 | 16.2K |
| 2024-09-26 | Camaisa Allan CEO and Chairman of the Board | Grant or award | 70.2K | 1.15 | 80.7K |
| 2024-06-28 | Stewart Alan R. Director | Grant or award | 73.4K | — | — |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| ARMISTICE CAPITAL, LLC | 209.9K | 879.0K |
| SABBY MANAGEMENT, LLC | 103.9K | 434.9K |
| Warberg Asset Management LLC | 59.5K | 250.0K |
| HighTower Advisors, LLC | 19.9K | 83.5K |
| GEODE CAPITAL MANAGEMENT, LLC | 15.0K | 63.0K |
| RS CRUM INC. | 9.6K | 40.3K |
| Arax Advisory Partners | 8.9K | 37.3K |
| JANE STREET GROUP, LLC | 8.3K | 34.8K |
| VANGUARD CAPITAL MANAGEMENT LLC | 6.1K | 25.5K |
| Belpointe Asset Management LLC | 4.8K | 19.9K |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Calidi Biotherapeutics GAAP EPS of -$2.94 · 2026-08-13
- Calidi Biotherapeutics, Inc. (CLDI) filed form 8-K · 2026-08-13 · SEC EDGAR
Ask the AI about CLDI
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →